Stéphane Bancel, Moderna CEO (Tom Williams/CQ Roll Call via AP Images)
Updated: Moderna ramps up R&D spend in RSV, flu and cytomegalovirus in Q2
When compared to the same quarter last year, R&D expenses at the mRNA powerhouse Moderna rose by 62% to $1.1 billion in this latest quarter …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
